Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
58.26
+0.48 (0.83%)
Apr 28, 2026, 4:00 PM EDT - Market closed
BMY Revenue
In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%. Bristol-Myers Squibb Company had revenue of $12.50B in the quarter ending December 31, 2025, with 1.30% growth.
Revenue (ttm)
$48.19B
Revenue Growth
-0.22%
P/S Ratio
2.47
Revenue / Employee
$1,482,892
Employees
32,500
Market Cap
118.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| GSK plc | 43.97B |
BMY News
- 4 days ago - Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy - Reuters
- 4 days ago - Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company - Business Wire
- 5 days ago - Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PRNewsWire
- 7 days ago - Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion - Business Wire
- 8 days ago - Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer - GlobeNewsWire
- 13 days ago - Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases - GlobeNewsWire
- 19 days ago - Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours - GlobeNewsWire
- 21 days ago - 15 stocks to put on your list to buy when the market recovers - Market Watch